Quantitative in silico Analytical Chemistry
21世紀　分析化学教室

2024-0915 Visualization XXXIII Against chronic kidney disease.pdf (1.09MB)

2024-0825 Visualization XXXII Covid-19 updated 3 Natural infection inhibitors.pdf (1.33MB)

2024-0815 Visualization XXXI Covid-19 updated 2 Practical use of current medicines.pdf (2.81MB)

2024-0805 Visualization XXX Covid-19 updated 1 Fundamental and Inhibition.pdf (1.93MB)

2024-0629 Visualization XXVII KP.2 and KP.3 binding with ACE-2.pdf (0.26MB)

 2024-0520 Visualization XXII JN.1 S-RBD and ACE-2 interaction inhibitors.pdf (0.58MB)

2024-0510 Visualization XXI Enantimers^LJ the wonderland.pdf (0.4MB)

2024-0503 Visualization XX Glycosylation Efective derivatization.pdf (0.72MB)

2024-0430 Visualization XIX Quantitative analysis of enzyme selectivity.pdf (0.18MB)

2024-0420 Binding inhibitor 18 RNA medicine candidates for kidney disease patients.pdf (0.31MB)

2024-0404 Binding inhibitors 17 Visualization XVII Selectivity of inhibitors against variants Delta, BA.2.86, and JN.1.pdf (0.48MB)

2024-0326 Binding inhibitor16, Quick search for advanced medicines.pdf (0.19MB)

2024-0320 Binding inhibitor 15 Advanced medicines.pdf (0.28MB)

2024-0305 Binding inhibitos 14 AI and auto dock.pdf (0.33MB)

2024-0222 Binding inhibitors 13 Chemical structure of binding inhibitors 2 Contribution of glycoside.pdf (0.34MB)

2024-0216 Binding inhibitors 12.pdf (0.36MB)

2024-0208 Binding inhibitors 11.pdf (0.4MB)

2024-0121 Binding inhibitors 10.pdf (0.48MB)

2024-0106 Binding inhibitos 9.pdf (0.44MB)

2023-1224 Bonding inhibitos 8.pdf (0.27MB)

2023-1222 Binding inhibitors 7.pdf (0.3MB)

2023-1122 Binding inhibitors 6.pdf (0.78MB)

2023-1103 Bonding inhibitors 5 Tea components.pdf (0.29MB)

2023-0916 Binding inhibitors 4.pdf (0.33MB)

2023-0825 Binding inhibitors 3.pdf (0.7MB)

2023-0815 Binding inhibitors 2.pdf (0.2MB)

2023-0808 Binding inhibitors.pdf (0.22MB)